What is GlucoTrack Intrinsic Value: Projected FCF?
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2024-12-12), GlucoTrack's Intrinsic Value: Projected FCF is $-10.41. The stock price of GlucoTrack is $0.28. Therefore, GlucoTrack's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.
The historical rank and industry rank for GlucoTrack's Intrinsic Value: Projected FCF or its related term are showing as below:
GCTK's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.76 * Ranked among companies with meaningful Price-to-Projected-FCF only.
GlucoTrack Intrinsic Value: Projected FCF Historical Data
The historical data trend for GlucoTrack's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of GlucoTrack's Intrinsic Value: Projected FCF
For the Medical Instruments & Supplies subindustry, GlucoTrack's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlucoTrack's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GlucoTrack's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where GlucoTrack's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
GlucoTrack's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
0.28
/
-10.412211910566
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlucoTrack Intrinsic Value: Projected FCF Related Terms
Thank you for viewing the detailed overview of GlucoTrack's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GCTK has been successfully added to your 